JP2009530281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530281A5 JP2009530281A5 JP2009500426A JP2009500426A JP2009530281A5 JP 2009530281 A5 JP2009530281 A5 JP 2009530281A5 JP 2009500426 A JP2009500426 A JP 2009500426A JP 2009500426 A JP2009500426 A JP 2009500426A JP 2009530281 A5 JP2009530281 A5 JP 2009530281A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- halo
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010023379 Ketoacidosis Diseases 0.000 claims 2
- 208000007976 Ketosis Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 0 *c1ccc(COc2cc(OCCCC3CC(O)=O)c3cc2)cc1 Chemical compound *c1ccc(COc2cc(OCCCC3CC(O)=O)c3cc2)cc1 0.000 description 4
Claims (15)
- 式I:
Aは、アリール基又はヘテロシクリル基から選択され、
Bは、5〜7員の炭素環又は複素環であり、
R1は、ハロ、シアノ、C1−C6アルキル、−OH又はC1−C6アルコキシから選択され、並びに
R2は、ハロ、C1−C6アルキル、−OH又はC1−C6アルコキシから選択され、
nは0、1又は2から選択され、
pは0、1又は2から選択され、
qは0、1又は2から選択され、
pが2である場合、各R1は独立に選択され、
qが2である場合、各R2は独立に選択され、
Rb及びRb’は、−H又はハロから独立に選択され、
上記アルキル、アリール及びヘテロシクリル基並びに複素環及び炭素環の各々は、
アミノ、
C1−C6アルコキシ、
ハロで置換されていても良いC1−C6アルキル、
アリール、
ハロ、
ヒドロキシル、
ヘテロアリール、
C1−C6ヒドロキシアルキル、又は
−NHS(O)2−(C1−C6アルキル)
から選択される1〜5個の置換基で置換されていても良い、アリール、ヘテロアリール、シクロアルキル又はヘテロシクリル、
各々が1個以上のヘテロ原子によって分断されていても良い、C1−C6アルキル、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、C1−C6アルキルアミノ、C2−C6アルケニル若しくはC2−C6アルキニル、
シアノ、
ハロ、
ヒドロキシル、
ニトロ、又は
−O−アリール
から選択される1〜3個の置換基で独立に置換されていても良く、
B環は、Bが4個のC原子を含む5員環である場合、BはO原子を含まないという条件で、オキソ基で更に置換されていても良く、又は式=CRaRa’の基(ここで、Ra及びRa’は、H又はC1−C4アルキル基から独立に選択される)を含んでいても良い]
を有する化合物、又は薬学的に許容されるその塩、エステル、溶媒和化合物、互変異性体もしくは立体異性体。 - nが1である、請求項1に記載の化合物。
- pが0である、請求項1又は2に記載の化合物。
- qが0である、請求項1〜3のいずれか一項に記載の化合物。
- Aが、置換されていても良いアリール基である、請求項1〜4のいずれか一項に記載の化合物。
- Aが、非置換フェニル基であり、又は少なくとも1個のシアノ、−CF3、C1−C6アルキル、−OH若しくはC1−C6アルコキシ基で置換されたフェニル基である、請求項1〜5のいずれか一項に記載の化合物。
- Aが、少なくとも1個のメチル基、メトキシ基、エトキシ基、プロポキシ基、ブトキシ基又はペントキシ基で置換されたフェニル基である、請求項1〜6のいずれか一項に記載の化合物。
- Bが、5又は6員の炭素環又は複素環である、請求項1〜7のいずれか一項に記載の化合物。
- Bが、5又は6員の炭素環である、請求項1〜7のいずれか一項に記載の化合物。
- 薬学的に許容される担体、希釈剤又は賦形剤と、請求項1〜10のいずれか一項に記載の化合物、薬学的に許容される塩、エステル、溶媒和化合物、互変異性体もしくは立体異性体と、を含む医薬組成物。
- II型糖尿病、肥満、高血糖、糖不耐性、インスリン抵抗性、高インスリン血症、高コレステロール血症、高血圧症、高リポタンパク血症、高脂血症、高トリグリセリド血症、異脂肪血症、代謝症候群、X症候群、循環器疾患、アテローム性動脈硬化症、腎疾患、ケトアシドーシス、血栓障害、腎症、糖尿病性神経障害、糖尿病性網膜症、性的機能不全、皮膚障害、消化不良、低血糖症、癌又は浮腫から選択される疾患又は症状を治療するための、請求項11に記載の医薬組成物。
- 疾患又は症状がII型糖尿病である、請求項12に記載の医薬組成物。
- II型糖尿病、肥満、高血糖、糖不耐性、インスリン抵抗性、高インスリン血症、高コレステロール血症、高血圧症、高リポタンパク血症、高脂血症、高トリグリセリド血症、異脂肪血症、代謝症候群、X症候群、循環器疾患、アテローム性動脈硬化症、腎疾患、ケトアシドーシス、血栓障害、腎症、糖尿病性神経障害、糖尿病性網膜症、性的機能不全、皮膚障害、消化不良、低血糖症、癌又は浮腫から選択される疾患又は症状を治療する医薬の製造における、請求項1〜10のいずれか一項に記載の化合物、薬学的に許容される塩、エステル、溶媒和化合物、互変異性体もしくは立体異性体の使用。
- II型糖尿病を治療する医薬の製造における、請求項1〜10のいずれか一項に記載の化合物、薬学的に許容される塩、エステル、溶媒和化合物、互変異性体もしくは立体異性体の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78270606P | 2006-03-14 | 2006-03-14 | |
US90520707P | 2007-03-05 | 2007-03-05 | |
PCT/US2007/006279 WO2007106469A2 (en) | 2006-03-14 | 2007-03-12 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009530281A JP2009530281A (ja) | 2009-08-27 |
JP2009530281A5 true JP2009530281A5 (ja) | 2010-04-22 |
Family
ID=38326178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009500426A Withdrawn JP2009530281A (ja) | 2006-03-14 | 2007-03-12 | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070244155A1 (ja) |
EP (1) | EP2001844A2 (ja) |
JP (1) | JP2009530281A (ja) |
AR (1) | AR059895A1 (ja) |
AU (1) | AU2007225208A1 (ja) |
CA (1) | CA2646430A1 (ja) |
MX (1) | MX2008011615A (ja) |
TW (1) | TW200804333A (ja) |
WO (1) | WO2007106469A2 (ja) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
US7572934B2 (en) * | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2008311355B2 (en) | 2007-10-10 | 2012-01-19 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
EP2215068B1 (en) * | 2007-10-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2716352C (en) * | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
JP2012503595A (ja) * | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
MX2011002199A (es) * | 2008-08-27 | 2011-05-10 | Arena Pharm Inc | Derivados de acidos triciclicos substituidos como agonistas del receptor s1p1 utiles en el tratamiento de trastornos autoinmunes e inflamatorios. |
US8748462B2 (en) * | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
KR20110082145A (ko) * | 2008-10-21 | 2011-07-18 | 메타볼렉스, 인코포레이티드 | 아릴 gpr120 수용체 작동약 및 이의 용도 |
AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
AU2010206786A1 (en) * | 2009-01-23 | 2011-07-28 | Merck Sharp & Dohme Corp. | Bridged and fused heterocyclic antidiabetic compounds |
US20120035196A1 (en) * | 2009-04-22 | 2012-02-09 | Kenji Negoro | Carboxylic acid compound |
CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
JP5746334B2 (ja) * | 2010-06-16 | 2015-07-08 | シマベイ セラピューティクス, インコーポレーテッド | Gpr120受容体作動薬及びその使用 |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2511273B8 (en) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014016648B1 (pt) * | 2012-01-12 | 2020-10-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica |
US9688695B2 (en) | 2012-04-26 | 2017-06-27 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
WO2013163244A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
AU2013344604B2 (en) | 2012-11-16 | 2017-07-27 | Bristol-Myers Squibb Company | Dihydropyrazole GPR40 modulators |
EP2953681B1 (en) * | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
ES2709195T3 (es) * | 2013-02-28 | 2019-04-15 | Tiumbio Co Ltd | Compuesto tricíclico y uso del mismo |
CN104109115B (zh) * | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
CN105246875A (zh) * | 2013-09-03 | 2016-01-13 | 四川海思科制药有限公司 | 茚满衍生物及其制备方法和在医药上的应用 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
HUE058819T2 (hu) | 2015-09-02 | 2022-09-28 | Trevena Inc | 6-tagú aza-heterociklusos delta-opioid receptort moduláló vegyületek, felhasználásuk és elõállításuk módszerei |
EP3436003B1 (en) | 2016-03-29 | 2023-08-23 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
CN109153670B (zh) | 2016-05-23 | 2022-03-15 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
BR112019016775A2 (pt) | 2017-02-17 | 2020-03-31 | Trevena, Inc. | Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos |
EP3582779B1 (en) | 2017-02-17 | 2024-04-17 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
AR111199A1 (es) * | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
CN109320483A (zh) * | 2017-08-01 | 2019-02-12 | 南京大学 | 香豆素衍生物、其制备方法及其作为药物的用途 |
EP3684767B1 (en) | 2017-09-22 | 2024-04-24 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
KR20200071752A (ko) | 2017-10-18 | 2020-06-19 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
SG11202004537UA (en) | 2017-11-24 | 2020-06-29 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物 |
CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7464920B2 (ja) * | 2018-12-06 | 2024-04-10 | シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド | 免疫調節としての芳香環誘導体及びその製造方法と使用 |
CN110156761B (zh) * | 2019-06-18 | 2022-08-09 | 郑州大学 | 含香豆素-联苯骨架化合物、制备方法及其应用 |
CN113880747B (zh) * | 2020-07-03 | 2023-05-26 | 上海美迪西生物医药股份有限公司 | 一种吲哚衍生物及其应用 |
CN114163426B (zh) | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
CN115340484A (zh) * | 2021-05-13 | 2022-11-15 | 上海美迪西生物医药股份有限公司 | 苄氧基吲哚类支链酸类衍生物及其制备方法和应用 |
WO2024109462A1 (zh) * | 2022-11-22 | 2024-05-30 | 西安新通药物研究股份有限公司 | 新型双环类pd-l1抑制剂及其制备方法与医药用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE305216B (ja) * | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
US6037367A (en) * | 1995-07-14 | 2000-03-14 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
JP4345230B2 (ja) * | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
US7238716B2 (en) * | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
CA2475434C (en) * | 2002-02-07 | 2011-04-05 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
US7214495B2 (en) * | 2002-02-14 | 2007-05-08 | Takeda Pharmaceutical Company Limited | Screening method |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
GB0214149D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
CA2527691C (en) * | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
CN1946666A (zh) * | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
US20060003344A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
PE20080069A1 (es) * | 2006-05-15 | 2008-02-22 | Merck & Co Inc | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) |
-
2007
- 2007-03-12 WO PCT/US2007/006279 patent/WO2007106469A2/en active Application Filing
- 2007-03-12 EP EP07752941A patent/EP2001844A2/en not_active Withdrawn
- 2007-03-12 MX MX2008011615A patent/MX2008011615A/es not_active Application Discontinuation
- 2007-03-12 AU AU2007225208A patent/AU2007225208A1/en not_active Abandoned
- 2007-03-12 JP JP2009500426A patent/JP2009530281A/ja not_active Withdrawn
- 2007-03-12 CA CA002646430A patent/CA2646430A1/en not_active Abandoned
- 2007-03-13 US US11/717,945 patent/US20070244155A1/en not_active Abandoned
- 2007-03-14 AR ARP070101028A patent/AR059895A1/es not_active Application Discontinuation
- 2007-03-14 TW TW096108813A patent/TW200804333A/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009530281A5 (ja) | ||
JP2011515341A5 (ja) | ||
NZ631569A (en) | Phenyl alkanoic acid derivatives as gpr agonists | |
JP2020033357A5 (ja) | ||
JP2013538802A5 (ja) | ||
JP2010510242A5 (ja) | ||
JP2008525417A5 (ja) | ||
WO2001016123A1 (en) | Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation | |
JP5786034B2 (ja) | 脂質異常症の治療に適したヘテロ環式化合物 | |
JP2007519695A5 (ja) | ||
CA2404384A1 (en) | Substituted 1,3-thiazole compounds, their production and use | |
CA2486399A1 (en) | Calcium receptor modulating agents | |
RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
JP2005513026A5 (ja) | ||
JP2010530438A5 (ja) | ||
JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
CA2558585A1 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
JP2012505896A5 (ja) | ||
JP2008511683A5 (ja) | ||
NO20081821L (no) | Forbindelser for behandling av metabolske forstyrrelser | |
JP2008530242A5 (ja) | ||
JP2006520755A5 (ja) | ||
PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
JP2007531764A5 (ja) | ||
JP2006516251A5 (ja) |